| Document |
Document Title |
|
WO/2019/186135A1 |
The present invention relates to radiolabelled olaparib and in particular [ 18 F]olaparib, a process for producing radiolabelled olaparib, and uses of radiolabelled olaparib in medical imaging.
|
|
WO/2019/183186A1 |
Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 t...
|
|
WO/2019/181017A1 |
Provided is a novel boron isotope (10B) tracing drug for use in neutron beam dynamic therapy (NBDT) and boron neutron capture therapy (BNCT). The novel boron isotope (10B) tracking-type drug represented by chemical formula 3 exhibits loc...
|
|
WO/2019/175405A1 |
6-[18HF]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [18F]...
|
|
WO/2019/169815A1 |
A radioactive molecular probe and an application thereof in detection of intravital islets, its structure is: formula (I), wherein R 1 are halogen, saturated aliphatic hydrocarbon group, unsaturated aliphatic hydrocarbon group and aromat...
|
|
WO/2019/166962A1 |
Crystalline Form M1 of deutetrabenazine is provided along with methods of its preparation. Deutetrabenazine may be useful in the treatment of a VMAT2-mediated disease and thus crystalline Form M1 of deutetrabenazine may be incorporated i...
|
|
WO/2019/166537A1 |
The present invention describes novel chelators (multidentate ligands) and precompounds for complexation of radiometals and non-radioactive counterparts, for use in radiopharmacy. The invention includes a process and a kit involving such...
|
|
WO/2019/165290A1 |
The invention provides a compound as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and methods for using such compounds and compositions. Formula (I).
|
|
WO/2019/158634A1 |
The present invention relates to deuterated derivatives of 9-(2,5-difluorophenethyl)-4- ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one having pharmacological activity, to processes of preparation of such compounds, to pharmaceutic...
|
|
WO/2019/152958A1 |
Provided herein are methods of fluorinating organic compounds. The electrochemical fluorination and radiofluorination of organic molecules using the cation pool technique is described, where the 18F and/or 19F-fluorine ions are added aft...
|
|
WO/2019/145292A1 |
The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies usin...
|
|
WO/2019/145294A1 |
The present invention relates to a novel method of preparing a compound of the formula I. Diagnostic compositions and their use in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's ...
|
|
WO/2019/145955A1 |
The present application provides a compound comprising at least one isotopically labeled nitrogen atom for use in diagnosing a condition or disease in a subject, compositions and kits comprising the compound and methods of using the same.
|
|
WO/2019/145291A1 |
The present invention relates to novel compounds of the formula (II) and formula (III) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and othe...
|
|
WO/2019/135386A1 |
The present invention provides a novel deuterated phospholipid and a method for producing same. The synthetic deuterated phospholipid according to the present invention can be used to address problems in the field. Antiphospholipid antib...
|
|
WO/2019/132117A1 |
The present invention provides a precursor compound for preparing a radioactive compound for efficiently imaging a heart, a radioactive compound prepared by using the precursor compound, and a use thereof as a contrast agent for PET imag...
|
|
WO/2019/129310A1 |
Disclosed are a deuterated elagolix derivative, a pharmaceutical composition, and uses thereof. The structure of the deuterated elagolix derivative of the present invention is as shown in formula (X). The deuterated elagolix derivative a...
|
|
WO/2019/131458A1 |
Provided are a compound represented by formula (1) or a salt thereof, and a medicine including the same. [In the formula, X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represent...
|
|
WO/2019/122255A1 |
The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known c...
|
|
WO/2019/126704A1 |
The invention provides deuterium-enriched isoindolinonyl-azepanediones, deuterium- enriched oxoquinazolin-3(4H)-yl-azepanediones, related compounds, pharmaceutical compositions, and methods of using such compounds and pharmaceutical comp...
|
|
WO/2019/123409A1 |
Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ...
|
|
WO/2019/109021A1 |
The disclosure provides processes for synthesizing compounds for use as CFTR modulators.
|
|
WO/2019/105913A1 |
The present invention relates to radiolabelled 4-(furo[3,2-c]pyridin-4-yl) derivatives and their use as radioactive tracers, and in particular their use as imaging agents.
|
|
WO/2019/104179A1 |
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
|
|
WO/2019/098291A1 |
This method uses a positron-emitting nuclide-labeled amino acid or a derivative thereof to synthesize a positron-emitting nuclide-labeled protein by means of a cell-free protein synthesis system. Said cell-free protein synthesis system i...
|
|
WO/2019/075574A1 |
The present application relates to conduritol aziridines of Formula (I), and uses thereof, for example, of 18F-labelled derivatives thereof in positron-emission tomography (PET) imaging of β-glucocerebrosidase activity.
|
|
WO/2019/073408A1 |
The invention provides an oral extended release formulation for the treatment of treatment- resistant depression, treatment-resistant anxiety, and phobia.
|
|
WO/2019/071130A1 |
The present provides a Positional Isotopomer NMR Tracer Analysis (PINTA) method thatcan be used to noninvasively assess rates of hepatic mitochondrial oxidation (VCS) and/or pyruvate carboxylase (VPC) flux in a subject. In certain embodi...
|
|
WO/2019/056251A1 |
The present invention relates to a group of isotope labeling reagents for amino/phenolic hydroxyl labeling, and a synthesis method therefor. In a synthesis process, a reagent (such as a homologue of 6-aminocaproic acid) carrying both ami...
|
|
WO/2019/055358A1 |
The present technology provides 13C- and 15N-labeled probes for imaging one or more mammalian cells using magnetic resonance. Thus, 13C- and 15N-labeled arginine (compound of formula I), xanthine (compounds of formula II and formula III)...
|
|
WO/2019/049918A1 |
The present invention relates to a method of mono-alkylating a piperidine nitrogen in a piperidine derivative with a deuterated lower-alkyl, which comprises protecting the piperidine nitrogen with an aralkyl protective group, lower-alkyl...
|
|
WO/2019/025137A1 |
The present invention refers to a process for transition-meta!-assisted 18F- deoxyfluorination of phenols. The transformation benefits from readily available phenols as starting materials; tolerance of moisture and ambient atmosphere, la...
|
|
WO/2019/027059A1 |
The purpose of the present invention is to produce a radiolabeled aryl compound by a simple method in which labeling can be carried out in a short time in high radiochemical yield and which renders the radiolabeled aryl compound usable i...
|
|
WO/2019/015690A1 |
A deuterated 3-quinuclidone compound, a preparation method, and a use. In particular, the present invention provides a compound shown in general formula I or a pharmaceutically acceptable salt, isomer or a mixture thereof, solvate, polym...
|
|
WO/2019/006078A1 |
Deuterated domperidone compositions, methods of synthesis, methods of use, and dosing formulations providing beneficial safety and other effects.
|
|
WO/2018/232777A1 |
A synthesis method for an aromatic compound containing a difluorodeuteromethoxy functional group or a difluorodeuterothio functional group. In the presence of an alkali, a difluorocarbene donor and Ar-(XH)n and heavy water undergo a reac...
|
|
WO/2018/235535A1 |
Provided is a production method for a radiohalogen-labeled compound, the method comprising: a step in which a radiohalogen-labeled precursor compound (S-L) including a leaving group (L) capable of nucleophilic substitution with a radioha...
|
|
WO/2018/213426A1 |
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. The compounds have the formula (I) wherein R is H or CH2OPO(OH)2. Also provided are pharmaceutical compositions comprising th...
|
|
WO/2018/206728A1 |
The invention relates to the use of a precursor for the production of carbon-11-labelled amino acids or derivatives thereof. According to the invention, the precursor is a compound of formula I: (formula I), where R1 and R2 are selected ...
|
|
WO/2018/189560A1 |
The invention relates to a process for post-preparation labelling of liposomal formulations with F (fluorine) isotope, wherein a) during the preparation of the liposomal formulation, a phospholipid derivative modified by terminal alkyne ...
|
|
WO/2018/176253A1 |
Provided are a group of isotope labelling reagents for carboxyl labelling and a synthesis method therefor, wherein one end of the isotope labelling reagent is a primary amine and the other end is a trimethyl ammonium salt; and the primar...
|
|
WO/2018/176512A1 |
The invention falls within the technical field of pharmaceutical compounds, and in particular relates to a deuterated palbociclib derivative, a preparation method and the use thereof. The deuterated palbociclib derivative has a structure...
|
|
WO/2018/183406A1 |
Composition, manufactures, and methods of making and using them, illustratively a process including the steps of: changing density of a composition including a neutron absorbent, the absorbent having a neutron absorption cross section gr...
|
|
WO/2018/171816A1 |
Disclosed in the present invention are a deuterated dipeptide boronic acid or an ester compound thereof, or a crystalline form, pharmaceutically acceptable hydrate or solvate thereof, the structure thereof being shown in formula (a), whe...
|
|
WO/2018/172243A1 |
The present invention is directed towards isomerically pure 18F-labelled (6S)-or (6R)-5-methyltetrahydrofolate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18F-labelled N-heterocycle...
|
|
WO/2018/168643A1 |
Provided is a method for producing [123I] ioflupane in a large quantity without deteriorating the quality thereof. The method is a method for producing radioactive-iodine-labeled ioflupane, comprising the steps of (a) reacting a labeling...
|
|
WO/2018/164043A1 |
Provided is a labeled precursor compound represented by formula (2). (In the formula, S represents a substrate, L represents a C1-6 linear alkyl group which may contain an ether group, R1 and R2 each independently represent a C1-30 linea...
|
|
WO/2018/165185A1 |
Long-term and high-density energy sources are described that utilize radioisotope batteries that provide a tritium (3H)-based direct energy conversion system. The beta radiation source is a nitroxide compound with a synthetic yield near ...
|
|
WO/2018/158137A1 |
The present invention provides a process to enhance the productivity such as yield of radioactive fluorine labeled flutemetamol. Provided is a process for producing a radioactive fluorine labeledflutemetamol, which comprises: (a) a step ...
|
|
WO/2018/153966A1 |
The present invention relates to novel compounds useful for visualizing cell sen es c en ce in vitro and in vivo, the preparation of said compounds and their use. In particular, the present invention pertains to novel hexose and particul...
|
